Will the experimental pancreatic cancer drug daraxonrasib be approved by the FDA by December 31, 2026?

🤖 Context

YES if the U.S. Food and Drug Administration officially grants marketing approval for daraxonrasib by December 31, 2026; NO otherwise.

How this market resolves

Predictions close on Jan 1, 2027, and the market is expected to resolve on Jan 2, 2027. The outcome will be settled against theweek.com. For now, the crowd puts YES at 29%, based on 0 predictions.

Key facts

Crowd probability

29%

Predictions made

0

Credits staked

0

Comments

0

Opened

May 31, 2026

Closes

Jan 1, 2027

Expected resolution

Jan 2, 2027

Resolution source

theweek.com

Frequently asked questions

When does this market resolve?

Predictions close on Jan 1, 2027, and it's expected to resolve on Jan 2, 2027.

What are the current odds?

The crowd currently gives YES about 29% and NO 71%, based on 0 predictions and 0 💎 staked.

How is this market settled?

It's settled against theweek.com once the outcome is known.

Is “Will the experimental pancreatic cancer drug daraxonrasib be approved by the FDA by December 31, 2026?” real-money betting?

No. “Will the experimental pancreatic cancer drug daraxonrasib be approved by the FDA by December 31, 2026?” is a free-to-play prediction market on Clutch: you predict with in-app credits, never real money, and can win points redeemable for real-world rewards.